HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

HYDROCORTISONE (HYDROCORTISONE SODIUM SUCCINATE)

から入手可能:

TEVA CANADA LIMITED

ATCコード:

H02AB09

INN（国際名）:

HYDROCORTISONE

投薬量:

250MG

医薬品形態:

POWDER FOR SOLUTION

構図:

HYDROCORTISONE (HYDROCORTISONE SODIUM SUCCINATE) 250MG

投与経路:

INTRAMUSCULAR

パッケージ内のユニット:

10

処方タイプ:

Prescription

治療領域:

ADRENALS

製品概要:

Active ingredient group (AIG) number: 0106344004; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2018-04-30

製品の特徴

page 1 of 7
PACKAGE INSERT
Sterile Powder
PR
HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION
BP
_ _
Glucocorticoid
_ _
ACTION AND CLINICAL PHARMACOLOGY
Hydrocortisone sodium succinate is a corticosteroid, and a highly
water soluble ester derivative of
hydrocortisone. It has the same metabolic and anti inflammatory
actions as hydrocortisone. High blood
levels of hydrocortisone are attained following intravenous injection.
Pharmacological effects have been noted within minutes and persist for
variable periods of time.
Excretion occurs primarily within 12 hours so that if high blood
levels need to be maintained
hydrocortisone injections are to be repeated every 4 to 6 hours. The
intravenous route is preferred for
initial emergency treatment.
INDICATIONS AND CLINICAL USE
Corticosteroid therapy is an adjunct to, and not a replacement for,
conventional therapy.
1. ENDOCRINE DISORDERS
Congenital adrenal hyperplasia; Hypercalcemia associated with cancer;
Primary or secondary
adrenocortical insufficiency or acute adrenocortical insufficiency
(hydrocortisone is the drug of
choice - it may also be used to supplement synthetic analogs);
Patients with known adrenal
insufficiency or when adrenocortical reserve is doubtful;
Preoperatively; Serious trauma or illness;
Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is suspected;
Nonsuppurative thyroiditis.
2. ALLERGIC STATES
Acute non infectious laryngeal oedema (though epinephrine is the drug
of first choice);
Control of severe or incapacitating allergic reactions:
Drug hypersensitivity reactions; Serum sickness; Seasonal or
perennial allergic rhinitis;
Urticarial transfusion reactions.
3. RESPIRATORY DISEASES
Aspiration
pneumonitis;
Berylliosis;
Bronchial
asthma;
Concurrently
with
appropriate
antituberculous chemotherapy in fulminating or disseminated pulmonary
tuberculosis; Loeffler's
syndrome not manageable by other means; Symptomatic sarcoidosis.
4. DERMATOLOGIC DISEASES
Atopic dermatitis; Bullous dermatitis herpetiformis; Contact
dermatiti